Device Trial Radar · NCT02107326
Randomized Crossover Study to Test the Impact of Using a Software for Smartphones and Tablets in Treating Type 1 Diabetes
Last checked: Nov 19, 2026Latest source record: Oct 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
May 2014
Primary completion
Aug 15, 2017
Study completion Oct 1, 2017
Sponsor
- Lead sponsor
- Philippe KleeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 8, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 10 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the impact of a software for smartphones and tablets on type 1 diabetes control and quality of life
Conditions
- Type 1 Diabetes
- Quality of Life
- Hypoglycaemia
Interventions
Webdia SoftwareDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effect of Webdia Software use on HbA1CTime frame: 0, 3, 6 and 9 months after inclusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital of Geneva
Geneva, Canton of Geneva, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.